Nutritional Formulation for Angelman Syndrome (FANS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03644693|
Recruitment Status : Unknown
Verified August 2018 by Jessica Duis, Vanderbilt University Medical Center.
Recruitment status was: Recruiting
First Posted : August 23, 2018
Last Update Posted : August 23, 2018
|Condition or disease||Intervention/treatment||Phase|
|Angelman Syndrome||Dietary Supplement: Nutritional Formulation Containing Exogenous Ketones Dietary Supplement: Placebo Formulation||Not Applicable|
An evaluation of the safety and tolerability of a nutritional formulation in Angelman syndrome in children ages 4-11 years.
Study is conducted over 16 weeks:
2 week baseline period - Patient continues on current dietary regimen they were on before joining the study (standard, ketogenic, or LGIT).
4 week intervention period - Patient consumes either placebo or nutritional formulation for 4 weeks, maintaining their current diet.
4 week washout period - Patient continues on current dietary regimen without consuming any study formulations.
4 week intervention period - Patient consumes either placebo or nutritional formulation for 4 weeks (crossover), maintaining their current diet.
2 week washout period - Patient continues on current dietary regimen without consuming any study formulations.
Follow-up phone call to be conducted by study personnel during this time.
Data is captured by the investigator during baseline, intervention, and washout periods, and by the parent/caregiver daily throughout the protocol using apps loaded on a provided tablet.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||15 participants|
|Intervention Model:||Crossover Assignment|
|Intervention Model Description:||The study design for this nutritional intervention protocol is a randomized, double blind, placebo controlled crossover study. Each patient will receive both nutritional formulation and placebo formulation, with a washout period between each arm. The dietary backgrounds will differ among patients. Acceptable diets include three basic diets: ketogenic diet (i.e. conventional 4:1 or 3:1, modified Atkins), low glycemic index diet (LGIT), and standard American diet (regular diet).|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Evaluation of the Safety and Tolerability of a Nutritional Formulation in Angelman Syndrome|
|Actual Study Start Date :||August 13, 2018|
|Estimated Primary Completion Date :||June 30, 2019|
|Estimated Study Completion Date :||June 30, 2019|
Subjects assigned to this arm will receive the Nutritional Formulation containing exogenous ketones.
Dietary Supplement: Nutritional Formulation Containing Exogenous Ketones
A nutritional formulation providing beta-hydroxybutyrate, 2g of carbohydrate, 1g of protein, and 9g of fat, plus minerals, per 100kcal. Given orally as food or beverage three times daily.
Placebo Comparator: Placebo
Subjects assigned to this arm will receive the Placebo Formulation.
Dietary Supplement: Placebo Formulation
A placebo formulation providing similar amounts of carbohydrates, proteins and minerals as the nutritional formulation. Given orally as food or beverage three times daily.
- Compliance with feeding protocol [ Time Frame: 16 weeks ]Tolerability will be demonstrated through patient compliance with the protocol as determined by the amount as measured in grams per day of nutritional formulation consumed as compared to the amount prescribed.
- Convenience, taste, and acceptability [ Time Frame: 16 weeks (measured 2 times) ]Parents/caregivers will rate convenience, taste, and acceptability of the nutritional formulation on a ten-point Likert scale. Each parameter will be rated individually with 1 = poor and 10 = excellent.
- Urinary Ketosis [ Time Frame: 16 weeks ]The degree of nutritional ketosis will be evaluated in patients with different dietary backgrounds when consuming the nutritional formulation. Urine ketones will be recorded daily as mmol of acetoacetate.
- Serum Ketosis [ Time Frame: 16 weeks (measured 3 times) ]The degree of nutritional ketosis will be evaluated in patients with different dietary backgrounds when consuming the nutritional formulation. Serum ketones will be recorded as mmol of R-beta-hydroxybutyrate.
- Number of Patients with Adverse Events [ Time Frame: 16 weeks (measured 3 times) ]All adverse events will be monitored throughout the study. The number and type of adverse event will be recorded.
- Change in Mobility Measured Using Zeno Walkway [ Time Frame: 16 weeks (measured 3 times) ]Patients with Angelman Syndrome typically have motor coordination and physical developmental delays resulting in an ataxic gate. As a measure of safety, the patient's gate characteristics for cadence will be compared to baseline.
- Change in Cognition as Measured by Event Related Potentials (ERP) [ Time Frame: 16 weeks (measured 3 times) ]Patients with Angelman Syndrome have global severe intellectual disability. As a measure of safety, ERP waveform amplitude and timing in response to a presented stimuli will be compared to baseline.
- Change in Cortical Irritability Measured Using Electroencephalogram (EEG) [ Time Frame: 16 weeks (measured 3 times) ]Patients with Angelman Syndrome have a characteristic EEG signature and are prone to seizure. As a measure of safety, the EEG signature will be compared to baseline in terms of the numbers of epileptiform discharges, notched delta and rhythmic theta activity.
- Number of Patients with Treatment Related Adverse Events as Assessed by Blood Metabolic Panel [ Time Frame: 16 weeks (measured 3 times) ]Blood samples will be taken and assessed for complete blood count, comprehensive metabolic panel, ketones, and lipids.
- Nutrient Intake [ Time Frame: 16 weeks ]Food diaries recorded daily to establish total caloric and macro-nutrient intake.
- Changes in Gastrointestinal (GI) Health [ Time Frame: 16 weeks ]Patients with Angelman Syndrome frequently suffer from poor GI health. As a measure of safety, bowel movements will be characterized daily according to the Bristol Stool Chart and compared to baseline.
- Changes in Sleep [ Time Frame: 16 weeks ]Patients with Angelman Syndrome frequently suffer from sleep issues. As a measure of safety, sleep duration and stage will be characterized by recording movement, heart rate and breathing during nighttime sleep and compared to baseline.
- Changes in Seizures [ Time Frame: 16 weeks ]A significant percentage of Patients with Angelman Syndrome suffer from epileptic seizures. As a measure of safety, the number and type of seizures that occur will be recorded daily in a diary and compare to baseline.
- Height [ Time Frame: 16 weeks (measured 3 times) ]Height (cm)
- Weight [ Time Frame: 16 weeks (measured 3 times) ]Weight (kg)
- Change from Baseline in the Vineland Adaptive Behavior Score [ Time Frame: 16 weeks (measured 3 times) ]Patients with Angelman Syndrome have severe global developmental delays. As a measure of safety, the Vineland Adaptive Behavior Scale, Third Edition will be used to measure changes from baseline in skills and independence.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03644693
|Contact: Jessica Duis||(615) firstname.lastname@example.org|
|United States, Tennessee|
|Vanderbilt University Medical Center||Recruiting|
|Nashville, Tennessee, United States, 37232|
|Contact: Jessica Duis, MD, MS 615-343-3249 email@example.com|
|Principal Investigator:||Jessica Duis, MD, MS||Vanderbilt University Medical Center|